Key result
Low-dose rivaroxaban cuts VTE risk ~33% vs antiplatelet therapy alone, but increases major bleeding.
Why the study?
Patients with ASCVD or chronic heart failure are at increased risk for venous thromboembolism, and although dual-pathway inhibition with low-dose rivaroxaban reduces arterial ischemic events, venous thromboembolic outcomes were not primary endpoints in the parent trials and remain underexplored.
Does dual-pathway inhibition with low-dose rivaroxaban (2.5 mg twice daily) added to background antiplatelet therapy reduce the risk of venous thromboembolism compared with antiplatelet therapy alone in adult patients with coronary artery disease, peripheral arterial disease, or chronic heart failure with concomitant coronary artery disease?
Meta-Analysis (n=29,864)
Does dual-pathway inhibition with low-dose rivaroxaban (2.5 mg twice daily) added to background antiplatelet therapy reduce the risk of venous thromboembolism compared with antiplatelet therapy alone in adult patients with coronary artery disease, peripheral arterial disease, or chronic heart failure with concomitant coronary artery disease?
Adding low-dose rivaroxaban to antiplatelet therapy in patients with ASCVD or heart failure reduces venous thromboembolism by 33% but increases major bleeding by 57%, resulting in a neutral venous-focused net clinical benefit.
Answers are grounded in this paper and cite their sources.
Supports VTE reduction with low-dose rivaroxaban plus antiplatelet therapy in ASCVD or HF; extends dual-pathway inhibition benefits to venous events.
Background: Patients with atherosclerotic cardiovascular disease (ASCVD), including coronary and peripheral artery disease, as well as those with chronic heart failure, remain at increased risk for venous thromboembolism (VTE). While dual-pathway inhibition (DPI) with low-dose rivaroxaban reduces arterial ischemic events, venous thromboembolic outcomes were not primary endpoints in the parent trials and remain underexplored. Research Question: In adult patients with coronary artery disease (CAD), peripheral arterial disease (PAD), or chronic heart failure with concomitant CAD, does dual-pathway inhibition with low-dose rivaroxaban (2.5 mg twice daily) added to background antiplatelet therapy reduce the risk of venous thromboembolism compared with antiplatelet therapy alone? Methods: This meta-analysis pooled data from randomized controlled trials comparing low-dose rivaroxaban combined with antiplatelet therapy against antiplatelet therapy alone. PubMed, Embase, Cochrane Library, Web of Science, and Scopus were searched up to March 2026. The primary outcome was overall VTE. Secondary outcomes included bleeding events, thrombotic events, VTE-related mortality, and a venous-focused net clinical benefit defined as symptomatic VTE versus fatal or critical organ bleeding. Hazard ratios (HR) or risk ratios (RR) with 95% confidence intervals (CIs) were pooled using fixed-effect models, heterogeneity assessed by I 2 , while study quality was evaluated through the ROB 2 and GRADE tools. Results: Three trials, including 29,864 participants (14,945 rivaroxaban; 14,919 control), were included. DPI significantly reduced the risk of VTE (RR: 0.67; 95% CI: 0.49-0.92; P=0.01; I 2 =0%). Reduction in pulmonary embolism did not reach statistical significance (RR: 0.64; 95% CI: 0.40-1.01; P=0.05), and no significant reduction was observed for deep vein thrombosis (RR: 0.72; 95% CI: 0.47-1.10; P=0.13). DPI was associated with a significantly increased risk of International Society on Thrombosis and Haemostasis (ISTH) major bleeding by 57% (HR: 1.57; 95% CI: 1.32-1.88; P<0.00001). No significant differences were observed in fatal bleeding (HR: 1.21; 95% CI: 0.72-2.06; P = 0.47), critical organ bleeding (HR: 1.04; 95% CI: 0.73-1.47; P = 0.84), or VTE-related mortality (RR: 0.71; 95% CI: 0.32-1.61; P = 0.41). Venous-focused net clinical benefit was neutral (RR: 0.91; 95% CI: 0.74-1.11; P=0.34). Overall risk of bias across included trials was low, with high certainty for the primary outcome. Conclusions: Low-dose rivaroxaban combined with antiplatelet therapy was associated with a reduction in VTE risk but an increased risk of major bleeding, without an improvement in net clinical benefit. These findings highlight the importance of individualized risk-benefit assessment when considering DPI for venous event prevention in patients with ASCVD or heart failure.
No takes yet. Share an insight, caveat, or question.
Murad et al. (2026) conducted a meta-analysis in Atherosclerotic cardiovascular disease (CAD or PAD) or chronic heart failure with concomitant CAD (n=29,864). Low-dose rivaroxaban plus antiplatelet therapy vs. Antiplatelet therapy alone was evaluated on Overall venous thromboembolism (VTE) (RR 0.67, 95% CI 0.49-0.92, p=0.01). Low-dose rivaroxaban plus antiplatelet therapy reduced venous thromboembolism risk vs antiplatelet therapy alone but increased major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: